Citadel Advisors
BHVN icon

Citadel Advisors’s Biohaven BHVN Stock Holding History

Citadel Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Sell
186,400
-85,800
-32% -$939K ﹤0.01% 6603
2025
Q4 		$3.07M Buy
272,200
+36,900
+16% +$457K ﹤0.01% 5109
2025
Q3 		$3.53M Buy
235,300
+49,500
+27% +$721K ﹤0.01% 4995
2025
Q2 		$2.62M Buy
185,800
+52,600
+39% +$937K ﹤0.01% 5202
2025
Q1 		$3.2M Buy
133,200
+64,400
+94% +$2.27M ﹤0.01% 4647
2024
Q4 		$2.57M Sell
68,800
-42,400
-38% -$1.98M ﹤0.01% 5127
2024
Q3 		$5.56M Sell
111,200
-12,100
-10% -$471K ﹤0.01% 3771
2024
Q2 		$4.28M Buy
123,300
+9,000
+8% +$356K ﹤0.01% 3992
2024
Q1 		$6.25M Buy
114,300
+52,000
+83% +$2.57M ﹤0.01% 3608
2023
Q4 		$2.67M Buy
62,300
+26,650
+75% +$829K ﹤0.01% 4859
2023
Q3 		$927K Sell
35,650
-11,400
-24% -$237K ﹤0.01% 6725
2023
Q2 		$1.13M Buy
47,050
+23,650
+101% +$407K ﹤0.01% 6218
2023
Q1 		$320K Sell
23,400
-11,200
-32% -$178K ﹤0.01% 9256
2022
Q4 		$480K Buy
+34,600
New +$489K ﹤0.01% 8328

Other funds holding BHVN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's BHVN Position: Q1 2026 in Review

Citadel Advisors reduced its Biohaven (BHVN) stake by 1.2% in Q1 2026, selling an estimated $228K and leaving 1,723,107 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Citadel Advisors first reported a position in BHVN in Q4 2022 and has held it in 14 quarters since. The position peaked at $87.7M in Q3 2024. 275 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

  • Citadel Advisors held 1,723,107 shares of Biohaven worth $14.6M as of Q1 2026.
  • Citadel Advisors sold 20,886 Biohaven shares in Q1 2026, an estimated $228K.
  • Biohaven made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2721 holding.
  • Citadel Advisors first reported a position in Biohaven in Q4 2022 and has held it in 14 quarters since.
  • Citadel Advisors's Biohaven position peaked at $87.7M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.